Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GY5Z
|
|||
| Former ID |
DAP000843
|
|||
| Drug Name |
Aspirin
|
|||
| Synonyms |
ACETYLSALICYLIC ACID; 50-78-2; 2-Acetoxybenzoic acid; o-Acetoxybenzoic acid; O-Acetylsalicylic acid; Polopiryna; Acylpyrin; Ecotrin; Easprin; Acetylsalicylate; Acetophen; Acenterine; Acetosal; Colfarit; Salicylic acid acetate; o-Carboxyphenyl acetate; Enterosarein; Aspergum; Salcetogen; Pharmacin; Acetosalin; Premaspin; Micristin; Benaspir; Aspirdrops; Acetonyl; Aceticyl; Temperal; Acetylin; Empirin; Ecolen; Rhodine; Endydol; Saletin; Rheumintabletten; Solprin acid; Acidum acetylsalicylicum; Globentyl; Pravigard
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Myocardial infarction [ICD-11: BA41-BA43] | Approved | [1] | |
| Pain [ICD-11: MG30-MG3Z] | Approved | [1], [2] | ||
| Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Phase 3 | [2], [3], [4] | ||
| Therapeutic Class |
Analgesics
|
|||
| Company |
Bayer Pharmaceuticals Corporation
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H8O4
|
|||
| Canonical SMILES |
CC(=O)OC1=CC=CC=C1C(=O)O
|
|||
| InChI |
1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
|
|||
| InChIKey |
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 50-78-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
4594, 87798, 476106, 602429, 829042, 832958, 840714, 3135921, 5261264, 7847177, 7885805, 7978731, 8143164, 8149208, 8151516, 10524572, 11110749, 11335730, 11360969, 11364139, 11364685, 11366701, 11367247, 11369263, 11369809, 11372248, 11372850, 11373537, 11375409, 11377425, 11377972, 11406615, 11461941, 11485574, 11489715, 11491110, 11491914, 11495059, 15195166, 17389202, 17390036, 17404602, 24278218, 24714725, 24890623, 24890723, 24891140, 26611613, 26679412, 26717767
|
|||
| ChEBI ID |
CHEBI:15365
|
|||
| ADReCS Drug ID | BADD_D00033 | |||
| SuperDrug ATC ID |
A01AD05; B01AC06; N02BA01
|
|||
| SuperDrug CAS ID |
cas=000050782
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Enterobacteriaceae
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Metabolic Effect | Increase activity | |||
| Description | Aspirin can be metabolized by Enterobacteriaceae, which results in the increase of the drug's activity. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Metabolic Effect | Increase activity | |||
| Description | Acetylsalicylic acid can be metabolized by Enterococcus, which results in the increase of the drug's activity. | |||
|
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Metabolic Effect | Increase activity | |||
| Description | Acetylsalicylic acid can be metabolized by Lactobacillus, which results in the increase of the drug's activity. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [6] | |||
| Microbial Enzyme | Carboxylesterase | |||
| Resulting Metabolite | Salicylic acid | |||
| Metabolic Effect | Increase side effect | |||
| Description | Aspirin can be metabolized to Salicylic acid by the carboxylesterase of gut microbiota, which results in the increase of the drug's side effect. | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides ovatus
Show/Hide Hierarchy
|
[7], [8] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Irritable bowel syndrome | |||
| Description | The abundance of Bacteroides ovatus was increased by Aspirin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacteriaceae
Show/Hide Hierarchy
|
[7], [8] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Irritable bowel syndrome | |||
| Description | The abundance of Bifidobacteriaceae was decreased by Aspirin. | |||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[7], [8] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Irritable bowel syndrome | |||
| Description | The abundance of Bifidobacterium was decreased by Aspirin. | |||
|
Studied Microbe: Bifidobacterium adolescentis
Show/Hide Hierarchy
|
[7], [8] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Irritable bowel syndrome | |||
| Description | The abundance of Bifidobacterium adolescentis was decreased by Aspirin. | |||
|
Studied Microbe: Bifidobacterium dentium
Show/Hide Hierarchy
|
[7], [8] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Irritable bowel syndrome | |||
| Description | The abundance of Bifidobacterium dentium was increased by Aspirin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia
Show/Hide Hierarchy
|
[7], [8] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Irritable bowel syndrome | |||
| Description | The abundance of Blautia was increased by Aspirin. | |||
|
Studied Microbe: Clostridium bolteae
Show/Hide Hierarchy
|
[7], [8] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Irritable bowel syndrome | |||
| Description | The abundance of Clostridium bolteae was increased by Aspirin. | |||
|
Studied Microbe: Eubacteriaceae
Show/Hide Hierarchy
|
[7], [8] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Irritable bowel syndrome | |||
| Description | The abundance of Eubacteriaceae was increased by Aspirin. | |||
|
Studied Microbe: Lachnospiraceae bacterium 3 1 57FAA CT1
Show/Hide Hierarchy
|
[7], [8] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Irritable bowel syndrome | |||
| Description | The abundance of Lachnospiraceae bacterium 3 1 57FAA CT1 was increased by Aspirin. | |||
|
Studied Microbe: Lachnospiraceae bacterium 7 1 58FAA
Show/Hide Hierarchy
|
[7], [8] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Irritable bowel syndrome | |||
| Description | The abundance of Lachnospiraceae bacterium 7 1 58FAA was increased by Aspirin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Streptococcaceae
Show/Hide Hierarchy
|
[7], [8] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Irritable bowel syndrome | |||
| Description | The abundance of Streptococcaceae was increased by Aspirin. | |||
|
Studied Microbe: Streptococcus
Show/Hide Hierarchy
|
[7], [8] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Irritable bowel syndrome | |||
| Description | The abundance of Streptococcus was increased by Aspirin. | |||
|
Studied Microbe: Streptococcus mutans
Show/Hide Hierarchy
|
[7], [8] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Irritable bowel syndrome | |||
| Description | The abundance of Streptococcus mutans was increased by Aspirin. | |||
|
Studied Microbe: Streptococcus parasanguinis
Show/Hide Hierarchy
|
[7], [8] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Irritable bowel syndrome | |||
| Description | The abundance of Streptococcus parasanguinis was increased by Aspirin. | |||
|
Studied Microbe: Streptococcus sanguinis
Show/Hide Hierarchy
|
[7], [8] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Irritable bowel syndrome | |||
| Description | The abundance of Streptococcus sanguinis was increased by Aspirin. | |||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HMG-CoA reductase (HMGCR) | Target Info | Inhibitor | [1] |
| Prostaglandin G/H synthase (COX) | Target Info | Inhibitor | [1], [9] | |
| BioCyc | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | |||
| Superpathway of cholesterol biosynthesis | ||||
| Mevalonate pathway | ||||
| KEGG Pathway | Terpenoid backbone biosynthesis | |||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| AMPK signaling pathway | ||||
| Bile secretion | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| TSH Signaling Pathway | ||||
| Panther Pathway | Cholesterol biosynthesis | |||
| Pathwhiz Pathway | Steroid Biosynthesis | |||
| WikiPathways | Statin Pathway | |||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | ||||
| Activation of Gene Expression by SREBP (SREBF) | ||||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| Integrated Breast Cancer Pathway | ||||
| SREBP signalling | ||||
| Cholesterol Biosynthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4139). | |||
| REF 3 | The mechanism of action of aspirin. Thromb Res. 2003 Jun 15;110(5-6):255-8. | |||
| REF 4 | Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232-5. | |||
| REF 5 | Gut microbiota modulates drug pharmacokinetics. Drug Metab Rev. 2018 Aug;50(3):357-368. | |||
| REF 6 | Gut Microbiota-Mediated Drug-Drug Interaction between Amoxicillin and Aspirin. Sci Rep. 2019 Nov 7;9(1):16194. | |||
| REF 7 | Interaction between drugs and the gut microbiome. Gut. 2020 Aug;69(8):1510-1519. | |||
| REF 8 | Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun. 2020 Jan 17;11(1):362. | |||
| REF 9 | Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.